Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focusing on dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior leadership team will engage in a fireside chat on Tuesday, December 3, 2024, at 9:00 a.m. ET in New York, NY, and will conduct investor meetings. A live webcast and replay of the presentation will be accessible on the company's website's Investors section under 'News & Events,' remaining available for at least 30 days after the event.
Zura Bio (Nasdaq: ZURA), un'azienda di immunologia in fase clinica che si concentra su anticorpi a doppio pathway per malattie autoimmuni e infiammatorie, ha annunciato la sua partecipazione al 36° Convegno Annuale sulla Salute di Piper Sandler. Il team dirigenziale senior dell'azienda parteciperà a una chiacchierata informale martedì 3 dicembre 2024, alle 9:00 ET a New York, NY, e condurrà incontri con investitori. Un webcast dal vivo e la replica della presentazione saranno accessibili nella sezione Investitori del sito web dell'azienda, sotto 'Notizie ed Eventi', e rimarranno disponibili per almeno 30 giorni dopo l'evento.
Zura Bio (Nasdaq: ZURA), una empresa de inmunología en etapa clínica que se centra en anticuerpos de doble vía para enfermedades autoinmunitarias e inflamatorias, ha anunciado su participación en la 36.ª Conferencia Anual de Atención Médica de Piper Sandler. El equipo de liderazgo senior de la empresa participará en una charla informal el martes 3 de diciembre de 2024, a las 9:00 a.m. ET en Nueva York, NY, y llevará a cabo reuniones con inversores. Una transmisión en vivo y la repetición de la presentación estarán disponibles en la sección de Inversores del sitio web de la empresa, bajo 'Noticias y Eventos', y permanecerán accesibles durante al menos 30 días después del evento.
주라 바이오 (Nasdaq: ZURA)는 자가면역 및 염증 질환을 위한 이중 경로 항체에 집중하는 임상 단계 면역학 회사로, 파이퍼 샌들러 제36회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 고위 경영진 팀은 2024년 12월 3일 화요일 오전 9시(ET)에 뉴욕에서 화상 대화에 참여하고 투자자 회의를 진행할 예정입니다. 생중계 및 발표의 재생은 회사 웹사이트의 투자자 섹션의 '뉴스 및 이벤트'에서 접근할 수 있으며, 이벤트 후 최소 30일 동안 제공됩니다.
Zura Bio (Nasdaq: ZURA), une entreprise d'immunologie en phase clinique spécialisée dans les anticorps à double voie pour les maladies auto-immunes et inflammatoires, a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. L'équipe de direction senior de l'entreprise participera à un entretien informel le mardi 3 décembre 2024 à 9h00 ET à New York, NY, et organisera des réunions avec les investisseurs. Un webcast en direct et la rediffusion de la présentation seront accessibles dans la section Investisseurs du site web de l'entreprise, sous 'Actualités et Événements', et resteront disponibles pendant au moins 30 jours après l'événement.
Zura Bio (Nasdaq: ZURA), ein Unternehmen für Immunologie in der klinischen Phase, das sich auf Dual-Pathway-Antikörper für autoimmune und entzündliche Erkrankungen spezialisiert hat, hat seine Teilnahme an der 36. jährlichen Healthcare-Konferenz von Piper Sandler bekannt gegeben. Das Führungsteam des Unternehmens wird am Dienstag, den 3. Dezember 2024, um 9:00 Uhr ET in New York, NY, an einem informellen Gespräch teilnehmen und Investorenmeetings abhalten. Ein Live-Webcast und eine Wiederholung der Präsentation sind im Investorenbereich der Unternehmenswebsite unter 'Nachrichten & Veranstaltungen' verfügbar und bleiben nach der Veranstaltung mindestens 30 Tage lang zugänglich.
- None.
- None.
A live webcast and a replay of the presentation will be available on the “News & Events” page within the Investors section of the Zura Bio website. The presentation will be archived on the website for at least 30 days following the events.
ABOUT ZURA BIO
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125900161/en/
Megan K. Weinshank
Head of Corporate Affairs
ir@zurabio.com
Source: Zura Bio Limited
FAQ
When is Zura Bio presenting at the Piper Sandler Healthcare Conference?
How can investors watch Zura Bio's Piper Sandler Conference presentation?
What type of company is Zura Bio (ZURA)?
What format will Zura Bio's presentation take at the Piper Sandler Conference?
